Therapeutic and Adverse Effect of Anti-PD1 Immunotherapy in Melanoma: A Retrospective, Single-Institute Study of 222 Patients.

Grethe Eikenes,Gabriella Liszkay,Tímea Balatoni,Kata Czirbesz,Karen Hunyadi,Zsófia Kozéki, Mihály Tamás Kispál,Fanni Baranyai,Tímea Danyi,Katalin Bőcs,István Kenessey

Cancers（2023）

引用 0|浏览5

暂无评分

摘要

Although the range of immunotherapeutic options is getting wider, in the management of melanoma patients, anti-PD1 monotherapy remains an important, effective, and safe method. However, significant correlation was found between the immune-related side effects and therapeutic efficacy.

查看译文

关键词

melanoma,single-institute

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要